1. Introduction {#sec1}
===============

Following the 2003 epidemic of severe acute respiratory syndrome (SARS), it was noticed that many patients who survived the severe illness developed residual pulmonary fibrosis, as shown by clinical findings and radiography. Varying degrees of fibrosis were also observed in autopsies of fatal cases. Although pulmonary fibrotic changes are occasionally observed as sequelae of other respiratory viral infections, they appear to be more common following SARS coronavirus (SARS-CoV) infection.

Given the threat of future outbreaks of severe coronavirus disease, including Middle East respiratory syndrome (MERS), it is important to understand the mechanisms responsible for pulmonary fibrosis, so as to support the development of therapeutic countermeasures and mitigate sequelae of infection. In this article, we summarize observations of pulmonary fibrosis during and after the SARS epidemic, note the extent to which fibrosis occurs after other pulmonary viral infections, describe efforts to recapitulate fibrotic changes in mouse models of SARS, and review evidence that the condition represents a hyperactive response to lung injury, driven by proinflammatory mediators acting through epidermal growth factor receptor (EGFR) signaling. We summarize work by our group and others indicating that inhibitors of EGFR may be useful in preventing an excessive fibrotic response in SARS and other respiratory viral infections, and indicate directions for future research.

2. SARS pathogenesis {#sec2}
====================

Severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic respiratory virus. SARS patients initially present with mild disease often consisting of persistent high fever, chills, malaise, myalgia, headache and dry cough that progressed in severity over the following weeks ([@bib40]). After an illness lasting 1--2 weeks, most patients resolve the infection, however about one-third develop severe pulmonary complications leading to acute lung injury and acute respiratory distress syndrome (ARDS), resulting in intubation and prolonged hospitalization ([@bib75]).

During the acute phase of SARS, lung damage results in edema, bronchiolar sloughing of ciliated epithelial cells and the deposition of hyaline-rich deposits at alveolar membranes, resulting in reduced gas exchange. During the next phase of infection (weeks 2--5), the lungs display signs of fibrosis, in which epithelial cells and alveolar spaces show fibrin deposition and infiltration of inflammatory cells and fibroblasts. During the final stage (weeks 6--8), pulmonary tissue becomes fibrotic with collagen deposits, and cellular proliferation is seen in alveoli and interstitial spaces ([@bib10], [@bib23], [@bib37]). Radiographic features of patient\'s lungs varied greatly by individual however characteristic features were present in most patients including progression from unilateral focal air-space opacity to multifocal or bilateral consolidation in the later phases of disease. Computer tomography (CT) of patients revealed consolidation with interstitial thickening in predominantly peripheral and lower lobes of the lungs ([@bib40], [@bib55]).

Multiple autopsy studies showed that diffuse alveolar damage (DAD) with hyaline membrane formation and interstitial thickening were common features of SARS-CoV infected lungs ([@bib8]). DAD occurs when there is trauma and injury to alveolar and bronchiolar epithelial cells that causes terminal small airways to be plugged with fluid and cellular debris, that can be seen both by pathological examination and radiological analyses ([@bib52], [@bib74]). In patients lacking hyaline membrane formation, acute fibrinous pneumonia with organizing phase fibrin deposition was observed, resulting in reduced lung function. Acute lung injury, squamous metaphasia, multinucleated giant cells, and extensive cellular proliferation were seen in all cases ([@bib44]).

Autopsies of SARS patients also showed lung fibrosis in various stages of progression ([@bib23], [@bib32], [@bib74]). These observations are not unique to SARS, but common to many lung disorders (see below). Importantly, clinical findings showed that older SARS patients had an increased risk of fibrosis ([@bib85]). The extent of fibrosis correlated with the severity and duration of illness ([@bib32], [@bib74]).

2.1. Follow-up of patients that have recovered from SARS-CoV infection {#sec2.1}
----------------------------------------------------------------------

Several studies have been conducted on patients who have resolved SARS-CoV infection. Many studies have reported an increased incidence of fibrosis in patients, even after SARS-CoV had been cleared. In one study, 45% of patients showed a "ground-glass" appearance, an indication of fibrosis, by chest X-ray scores and high-resolution computerized tomography by one month after infection ([@bib88]) ([Fig. 1](#fig1){ref-type="fig"} A). Ground-glass opacification in the lungs describes regions that display a hazy attenuated signal under CT imaging, without obscuring normal bronchial and vascular structures. The differential diagnosis for ground-glass opacification can be an infection, pulmonary edema, interstitial thickening or fibrotic deposits ([@bib11]). In a second study looking at the intermediate recovery periods of 3 and 6 months after infection, fibrotic features, including abnormal scoring of airspace opacity and reticular shadowing, were seen in 36% and 30% of the patients respectively (D. S. [@bib29], [@bib30]). A one year follow-up study on 97 recovering SARS patients in Hong Kong showed that 27.8% of SARS survivors showed decreased lung function and increased lung fibrosis compared to a normal population (David S. [@bib29], [@bib30]). Other follow-up studies have shown similar results (D. S. [@bib29], [@bib30], [@bib51], [@bib51]). The molecular pathways responsible for the development of SARS-CoV induced fibrosis observed in recovered patients are not well understood. This gap in knowledge limits the development of novel therapies targeting the development of fibrosis or the repurposing of existing treatments that may be effective against SARS-CoV induced fibrosis after infection.Fig. 1Pathologic features of SARS-CoV infection in humans and mice. A. Transverse thin-section CT scan in 36-year-old man at follow-up (obtained at day 43 after admission, 26 days since discharge) shows evidence of fibrosis. Large areas of ground-glass opacification are still present, both surrounding the areas of fibrosis and in other regions. (Permission for reuse from Antonio et al., Radiology [@bib95]; 228:810--815.) B. H&E stained lungs from either PBS or SARS-CoV (MA15) inoculated mice in wildtype 129/Sv or 129/STAT1-/- mice at 9 days post-infection. Note the resolution of lung damage and inflammation in the infected 129/Sv mice while 129/STAT1-/- mice display extensive inflammation, fibrotic lesions surrounding airways and occlusion of alveolar space with proteinaceous fluid and a mixed inflammatory infiltrate.Fig. 1

3. Animal models of SARS {#sec3}
========================

Non-human primate and small animal models are available to recreate various clinical aspects of SARS ([@bib69]). Among non-human primate models, cynomolgus and rhesus macaques, African green monkeys and common marmosets can all produced different levels of the clinical signs of disease seen in humans ([@bib69]). However, findings are often not consistent due to biological variability between animals.

Small animal models include ferrets, Syrian golden hamsters, and inbred mice. Ferrets and hamsters show virus replication in their lungs when infected intranasally with SARS-CoV. Hamsters show lung pathology (interstitial pneumonitis, pulmonary consolidation and diffuse alveolar damage) but conflicting symptoms are reported in ferrets ([@bib69]).

3.1. Mouse models to study SARS-CoV pathogenesis {#sec3.1}
------------------------------------------------

A variety of mouse models for SARS-CoV have been developed that range from mild to severe disease depending on the viral strain and mouse background used. When the SARS-CoV (Urbani) strain is used to intranasally infect BALB/c, C57B/6, or 129/S strains of mice, there is viral replication in the lungs with no spread to other organs ([@bib20], [@bib60], [@bib68]). Infection is found to cause focal peribronchiolar and perivascular inflammation by 3 days post infection. Through 7 days post infection, SARS-CoV (Urbani) is largely cleared from lungs with minimal effects on weight loss or clinical symptoms of infection. Lung pathology over this time period is minimal as well, outside of the denuded bronchi around day 2 post infection. Minimally apparent peribronchiolar, perivascular or interstitial inflammation is noted in these infections.

A SARS-CoV strain with significant weight loss, clinical disease and lung pathology was created by blind passage of SARS-CoV (Urbani) in adult BALB/c mice. A mouse-adapted strain of SARS-CoV (called MA15, 15 passages before 100% mortality was produced) emerged which produced severe disease and death in young and old BALB/c mice ([@bib18], [@bib59]). This virus carries 6 mutations in the genome: 4 in the replicase proteins and 2 in the structural proteins. In contrast to the SARS-CoV (Urbani) parent strain, the pulmonary pathology of mice infected with MA15 virus showed a rapid progression of inflammatory changes and more extensive damage to bronchiolar and alveolar epithelial cells. Intracellular MA15 antigens were highly prevalent in bronchiolar epithelium and alveolar pneumocytes with necrotic debris observed within the alveoli and the bronchiole lumen of mice ([@bib59]).

4. Molecular pathways involved in SARS-CoV pathogenesis {#sec4}
=======================================================

The MA15 strain of SARS-CoV has proved invaluable as a tool to understand host pathogen interactions in mouse models. Several knockout strains of mice infected with MA15 have identified immune factors that are critical for protection from SARS-CoV pathogenesis. To study the innate immune response to SARS-CoV, MyD88-/- mice were infected with MA15 which resulted in increased pulmonary inflammation and tissue damage with greater than 90% mortality by day 6 post-infection. In addition, MyD88^−/−^ mice had significantly higher SARS-CoV viral loads in lung tissue throughout the course of infection demonstrating a critical role of the MyD88 innate immune signaling pathway for clearance of and protection from SARS-CoV ([@bib65]). In addition to MyD88, TLR3 signaling through the TRIF adapter protein has been shown to regulate SARS-CoV pathogenesis as well again showing that deletion of either critical innate immune signaling molecules led to more severe disease ([@bib73]). Recently, the use of a systems biology approach combining pathogenesis and transcription profiling identified the urokinase pathway as a key node in controlling lung damage and fibrin deposition during SARS-CoV infection ([@bib22]). In these experiments, Serpine1, which regulates the deposition of fibrin after lung damage, is shown to have regulatory control over lung pathogenesis in the MA15 mouse model of SARS-CoV.

In 2004, Hogan et al. showed that mice deficient in the interferon-activated transcription factor Signal Transducer and Activator of Transcription 1 (STAT1) were much more susceptible to pathogenesis caused by SARS-CoV ([@bib27]). The authors attributed the findings to the role of STAT1 in interferon signaling. However, we have shown that the type I, II and III interferon pathways are largely dispensable for protection against SARS-CoV infection with mice deleted for the Type I IFN receptor, Type II IFN receptor or treated with IFN lambda neutralizing antibody displayed disease comparable with that seen in wildtype mice ([@bib19]). All were still permissive to SARS-CoV and displayed 10% weight loss during the first 4 days of the infection however they proceeded to regain weight and were able to reduce the levels of virus in their lungs through 9 days post infection. STAT1 knockout mice showed a higher propensity to develop fibrotic lesions compared to wild-type (WT) mice after SARS-CoV infection and showed increased pathogenesis even after SARS-CoV was cleared from lungs ([@bib54]) ([Fig. 1](#fig1){ref-type="fig"}B). Transcriptome analysis of SARS-CoV infected mouse lungs showed that STAT1 knockout mice developed a Th2 bias in their immune response ([@bib94]). The Th2 bias results in higher numbers of a subtype of macrophages in the lung, called alternatively activated macrophages (AAM), which in turn causes an overactive wound healing environment that induces pulmonary fibrosis ([@bib54]). AAMs are normally involved in clearing cell debris in damaged tissue after injury ([@bib21]). However in the study described in Page et al., AAMs are persistent in the lungs of Stat1 -/- mice where they become hyperactivated leading to increased fibrosis. This was similar to what was seen in a bleomycin induced fibrosis model where STAT1-/- mice developed higher rates of fibrosis after bleomycin treatment ([@bib79]).

To summarize, the adverse pathogenic effects of SARS-CoV seen in human patients was modeled in STAT1-deficient mice where fibrosis evident in these mice by an overproliferation of fibroblasts and enhanced inflammatory response to infection. The signaling pathways resulting upstream or downstream of STAT1 and in which cell types are responsible for the host response to SARS-CoV seen in humans is still unknown.

5. Induction of fibrosis by other viruses {#sec5}
=========================================

Induction of fibrosis is not unique to SARS-CoV. A recent meta-analysis of global idiopathic pulmonary fibrosis (IPF) rate finds that from the year 2000 onwards, a conservative incidence range of 3--9 cases per 100,000 per year for Europe and North America ([@bib31]). In the case of patients suffering from IPF, there is no known trigger for the onset of disease but viral infections are thought to be a co-factor ([@bib49], [@bib76]). Herpesviruses, such as Epstein-Barr virus (EBV) or human cytomegalovirus (HCMV), adenovirus, transfusion-transmitted virus (TTV, also known as Torque Teno Virus) and hepatitis C virus (HCV) have all been associated with IPF disease by detection of antibodies against viral proteins or viral gene products in lungs of IPF patients ([@bib49]). Elevated serum levels of chemokines (such as transforming growth factor Beta 1 (TGF-β1)) and development of pulmonary fibrosis have also been reported in influenza A (H1N1) virus-infected patients ([@bib80]). Irrespective of the etiology, pulmonary fibrosis has been shown to develop after apparent recovery from the infection. These studies only correlate the presence of a virus with IPF and it is unclear if and how the viruses directly trigger the disease or just create the conditions required for the development of pulmonary fibrosis caused by a secondary trigger (e.g. toxins, particulates or radiation) ([@bib49], [@bib87]). This suggests that the some of the pathways induced by SARS-CoV infection that lead to the observed pulmonary fibrosis may be shared irrespective of the damage inducing factor.

In humans, acute viral infection often leads to the development of acute respiratory distress syndrome (ARDS), resulting from acute lung injury ([@bib5]). Histological analysis shows that 64% of ARDS patients may have pulmonary fibrosis (PF) during recovery ([@bib43]). To demonstrate mechanistic correlation between viral infection, ARDS and PF, mouse models of viral infection has been utilized. Animal studies have produced additional evidence that viruses can trigger fibrosis. Murine gamma-herpesvirus 68 (MHV-68) infects mouse lungs and was shown to trigger pulmonary fibrosis in interferon (IFN)-γ receptor knockout mice (IFN-gammaR -/-) ([@bib48]). Additionally, when an anti-viral drug cidofovir was used post infection, it resulted in protection from pulmonary fibrosis ([@bib47]). A similar protective effect was seen in infections involving a mutant MHV-68 that was defective for reactivation from latency suggesting a connection between virus life cycle and lung fibrosis for this virus ([@bib47]).

Respiratory syncytial virus (RSV) is the leading pediatric respiratory virus, resulting in high morbidity and mortality worldwide ([@bib57]). RSV infection causes significant acute lung injury with the potential for ARDS and other pulmonary complications ([@bib57]). In mouse models of RSV infection, it was shown that mouse airways that were pre-sensitized with ovalbumin (OVA), a common model for studying asthma and immune responses to lung infections in mice, were much more likely to develop fibrosis ([@bib4]). Another study showed RSV infection caused pulmonary fibrosis in C57Bl/6 mice and showed enhanced pathology in combination with cigarette smoke ([@bib17]).

Taken together, these data indicate that there\'s a strong correlation between respiratory viral infections and the development of pulmonary fibrosis in humans. Animal models suggest that virus infection either alone on in combination with immune modulation could be triggers for the onset of fibrosis at least in some viruses. However, the molecular mechanisms following the viral infection that ultimately result in fibrosis have largely remained unexplored.

6. Current efforts to understand fibrosis induction by SARS-CoV {#sec6}
===============================================================

The normal wound healing response can be categorized into three distinct steps ([@bib82]). The first step is the injury step during which disrupted epithelial and endothelial cells initiate an anti-fibrinolytic cascade that produces a temporary patch on the wound. The second step is the inflammation step where circulating neutrophils, macrophages and fibrocytes infiltrate to the site of injury. The recruited inflammatory cells secrete additional profibrotic cytokines such as IL-1, TNF, IL-13, and TGF-β. Macrophages and neutrophils also remove cell debris and eliminate pathogens. This in turn is followed by the proliferation and differentiation of fibroblasts into myofibroblasts, the key cell type that coordinates wound repair. Myofibroblasts secrete new ECM components on which tissue is rebuilt ([@bib86]). Finally, the third step involves resolution of the wound healing process, where myofibroblasts contract to reduce the size of the wound and its population numbers decrease by undergoing apoptosis.

Analysis of lung biopsies from SARS-CoV infected people shows dysregulation of this normal wound healing response ([@bib6]). Pro-inflammatory cytokines IFN-γ, IL-6, TNF-α, IL-18, CXCL10, MCP1 and TGF-β were found to be highly upregulated in serum from SARS-CoV patients ([@bib28], [@bib83]). TGF-β1 was also found to be upregulated in mouse models of SARS-CoV infection similar to what was observed in other respiratory virus infections ([@bib3], [@bib61]). This is significant due to the profibrotic nature of TGF-β1. The release of TGF-β from injured tissue promotes lung repair, which while normally lead to resolution of infection, in SARS-CoV infection it often leads to hyperactivation of the TGF-β pathway leading to the promotion of lung fibrosis. In animal models of TGF-β regulation, transgenic mice over-expressing TGF-β show produce severe pulmonary fibrosis in mice and rats ([@bib67]). The TGF-β activation pathways leads to the production of fibrin, collagen and secreted proteases (Matrix metalloproteinases). TGF-β's role in cellular proliferation is under investigation, however there is evidence it is a key factor in the epithelial--mesenchymal transition (EMT) seen in repaired tissue. TGF-β's presence in the lungs is required to promote lung fibroblasts to differentiate into myofibroblasts that are important in repairing lung tissue. However, under high and sustained levels of TGF-β, persistence of the repair process results in further damage.

7. The role of epidermal growth factor receptor signaling in fibrotic disorders {#sec7}
===============================================================================

We have previously published work demonstrating that in STAT1-/- mice infected with the mouse adapted strain of SARS-CoV (called MA15) there is significant lung damage that occurs during infection and proceeds at later time points to the development of fibrosis in the lungs of infected mice. Transcriptomic analysis of lungs undergoing MA15 infection found a significant time-dependent up-regulation of several pathways including M2 macrophage induction, chemokine dysregulation compared to other viral lung infections and the induction of wound healing genes. When analyzed, the wound healing pathway is led by the EGFR protein. Wound healing genes are regulated by EGFR signaling ([@bib81]) which suggests that EGFR signaling may play a role in the development of fibrosis in SARS patients.

7.1. Overview of EGFR signaling {#sec7.1}
-------------------------------

EGFR (named ErbB1 or human epidermal growth factor receptor 1 \[HER1\] in humans) is the prototypical member of a family of receptor tyrosine kinases known as the ErbB receptors. There are four known members in the ErbB family, the other three being HER2 (ErbB2/NEU), HER3 (ErbB3) and HER4 (ErbB4) ([@bib35]). Ligand binding to an extracellular domain triggers conformational changes resulting in the dimerization of the receptors. The ErbB receptors all possess an intrinsic tyrosine kinase activity and can phosphorylate themselves. Specific tyrosine residues in the cytoplasmic tail are phosphorylated resulting in the activation of signaling to the MAPK, Akt and JNK pathways ([@bib91], [@bib92]).

Activation of EGFR signaling has a range of outcomes, such as the inhibition of apoptosis, increase in cell proliferation and migration, activation of the inflammatory response and increase in mucus production ([@bib92]). EGFR is expressed in tissues derived from epithelial, mesenchymal and neuronal origin ([@bib90]). EGFR signaling is especially important in tissue that undergo extensive turnover of cells such as in the epithelial layers of the skin, lungs and gut. EGFR activation in skin keratinocytes leads to cell proliferation, migration and cell survival required for wound healing. In the lungs and gut, EGFR signaling plays a role in controlling cell turnover and mucus production.

The role of EGFR has been well studied in the context of cancer especially non-small cell lung cancer where mutations in EGFR are routinely found. Small molecule tyrosine kinase inhibitors (TKIs) like Gefitinib and Afatinib as well as monoclonal antibody based treatments like Cetuximab have been developed as chemotherapy agents to inhibit the activity of EGFR ([@bib36], [@bib41], [@bib90]). However, since EGFR signaling also regulates wound healing and repair in normal tissue, it has also been associated with fibrotic disease in various organs.

8. The ligands of EGFR {#sec8}
======================

There are seven known identified ligands of EGFR ([@bib63]) ([Fig. 1](#fig1){ref-type="fig"}): EGF, transforming growth factor alpha (TGF-α), amphiregulin (AR), epiregulin (EREG), heparin binding epidermal growth factor (HB-EGF), epithelial mitogen or epigen (EPGN) and betacellulin (BTC). All EGFR ligands are expressed as transmembrane precursor proteins that are cleaved by cell surface proteases upon injury or another signaling event and then released into the extracellular milieu as mature proteins, where they can bind the extracellular domain of EGFR.

Structurally, all the EGFR ligands possess at least one EGF module ([Fig. 2](#fig2){ref-type="fig"} ), which is processed and released by the 'a disintegrin and metalloproteinase' (ADAM) family of metalloproteases ([@bib64]). The soluble fragment containing the EGF module serves as the activating ligand for EGFR ([@bib63]). EGF has nine EGF modules but only the first one is released and serves as an EGFR ligand. All the other canonical ligands have a single EGF module. The C-terminal tails of the ligands are also known to function as potential transcriptional co-factors by translocating to the nucleus after proteolytic cleavage ([@bib38], [@bib50]).Fig. 2The seven known ligands of EGFR are in a membrane bound inactive form. The ADAM family of proteases are activated in response to tissue injury and cleave the pro-ligands to release the EGF module containing soluble ligand. The ligand binds to the receptor causing it to dimerize and autophosphorylate its C-terminal tail at specific tyrosine residues. The phosphorylated active form aggregates several adaptor proteins leading to the activation of multiple signaling cascades. A range of different outcomes are produced by the activation of these pathways some of which are listed in the schematic above.Fig. 2

In polarized human airway epithelial cells, the ligands are expressed in their pro-form in the apical membranes and the receptors are expressed in the basolateral surfaces of the cells ([@bib77]). This spatial segregation of receptors from the ligand maintains the receptor in an inactive state during homeostasis. Upon injury, the epithelial barrier is compromised allowing airway surface liquid (ASL) containing small amounts of shed ligands to contact the basolateral surfaces of the epithelium and activate the receptor ([@bib14], [@bib77]). This step initiates the wound healing response.

9. EGFR signaling and the induction of fibrosis {#sec9}
===============================================

The role of EGFR signaling in fibrosis development is complex, with evidence for both a pro-fibrotic and anti-fibrotic role for EGFR signaling.

Cancer patients treated with tyrosine kinase inhibitors show an increased incidence of interstitial lung disease (ILD) which is often a precursor to pulmonary fibrosis ([@bib36]). Similar association with ILD were also seen in patients treated with an anti-EGFR monoclonal antibody, Panitumumab ([@bib53], [@bib89]). Gefitinib also exacerbates pulmonary fibrosis induced by bleomycin in mice ([@bib70]). These data suggest that inhibiting EGFR signaling increases the risk of pulmonary fibrosis, therefore suggesting that EGFR is anti-fibrotic in specific contexts.

However, TGF-β1 is known inducer of fibrosis and studies show it potently induces the expression of the EGFR ligand AR. Silencing AR by RNAi or using EGFR specific small molecule inhibitors such as AG1478 or Gefitinib, attenuated the fibrogenic effects of TGF-β1 ([@bib93]), contrasting with the bleomycin model of injury where Gefitinib made fibrosis worse ([@bib70]) and where TGF-β1 protected mice from bleomycin injury ([@bib72]). Furthermore, mice overexpressing the EGFR ligand TGF-α spontaneously develop lung fibrosis ([@bib24], [@bib26]). Similar effects for other EGFR ligands are discussed in more detail in the section below. These studies seem to indicate that EGFR signaling is pro-fibrotic.

How can we reconcile these seemingly conflicting data? One possibility is that EGFR signaling has different outcomes in different species and for different fibrotic triggers. An alternate possibility is that fibrosis may be a result of dysregulation in the kinetics of EGFR signaling rather than simply the strength of the signal at a given time point. Deposition of fibrotic material is a normal component of the wound healing response, but it is unresolved wound healing that results in fibrotic disease ([@bib1], [@bib7]). The dysregulated control of either the upregulation of EGFR signaling, which is required for the initiation of normal wound healing, or downregulation of EGFR signaling, which is required for the resolution of the wound healing process, could result in fibrotic disease ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3The potential role of EGFR in fibrosis is illustrated above with the lung as an example. Physical injury or a pathogen (1) initiates the wound healing response by damaging healthy tissue, releasing EGFR ligands (2) and activating the EGFR pathway. A sustained activation of the EGFR pathway results in an exaggerated wound healing response leading to a fibrotic lung (3). The early use of tyrosine kinase inhibitors (4) could prevent the normal progress of wound healing and result in sustained injury and the development of fibrosis by alternate mechanisms.Fig. 3

10. Animal models available to study EGFR and fibrosis {#sec10}
======================================================

The role of EGFR in fibrosis progression has been investigated using *in vivo* models, primarily mice. Mice lacking EGFR/HER1 die *in utero* ([@bib46]). Models of EGFR transgenic mice with overactive EGFR mutations seen in human cancers have been made that demonstrate the rapid development of lung tumors depends on EGFR signaling ([@bib58]). Mice containing EGFR mutations that lead to constitutive activation (DSK5 mice) show a skin related phenotype showing wavy hair, thick epidermis and darkened pigmentation ([@bib16]). Mice deficient in TGF-α, that lack EGFR signaling, are protected from chronic lung disease in models of lung damage ([@bib42]). Finally, in bleomycin induced fibrosis models in mice, the tyrosine kinase inhibitor Gefitinib is able to mitigate the onset of fibrosis ([@bib33]). Little is known about how alterations in EGFR signaling could be causing pulmonary fibrosis after a viral infection. However, by using these models, it has been demonstrated that EGFR regulation is a key pathway in the induction of damage induced pulmonary fibrosis.

A majority of the canonical EGFR ligands appear to play a role in promoting fibrosis in various organs (data summarized in [Table 1](#tbl1){ref-type="table"} ). These data show that constitutive ubiquitous expression of some EGFR ligands, resulting in constant EGFR activation results in the activation of fibrosis. The inhibition of EGFR signaling by using TKIs or by co-expressing signaling defective EGFR mutants reverses the onset of fibrosis, at least in the case of TGF- α overexpressing mice ([@bib25], [@bib26]).Table 1Several groups have constructed transgenic mice expressing the known EGFR ligands. These mice are viable and show different fibrosis-related phenotypes as summarized above. Knockout mice are mostly viable except in the case of HB-EGF. The knockouts showed increased resistance to fibrosis in the case of TGF- α and AR and increased sensitivity to fibrosis in HB-EGF/BTC double-knockouts.Table 1LigandPhenotype in transgenic overexpression modelPhenotype in knockout miceBetacellulin (BTC)Increased post-natal mortality due to lung pathology ([@bib62])BTC-knockout mice show no phenotype but BTC/HB-EGF double-knockouts show cardiac fibrosis ([@bib34])Epidermal Growth Factor (EGF)Defects in growth and spermatogenesis ([@bib9], [@bib84]); No fibrotic defects reportedNo fibrosis-related phenotype reportedTransforming Growth Factor alpha (TGF- α)Spontaneous fibrosis 1 week after birth ([@bib24])Resistance to Bleomycin-induced fibrosis ([@bib42])Heparin Binding Epidermal Growth Factor (HB-EGF)Pancreas specific overexpression resulted in pancreatic fibrosis ([@bib45])KO mice die shortly after birth; BTC/HB-EGF double-knockouts show cardiac fibrosis ([@bib34]); HB-EGF conditional knockout-induced liver fibrosis in a bile duct ligation model ([@bib71])Amphiregulin (AR)Pancreas specific overexpression resulted in pancreatic fibrosis ([@bib78]); Role in liver fibrosis ([@bib56])Knockout mice were significantly resistant to bleomycin-induced lung fibrosis ([@bib15])Epiregulin (EREG)No overexpression model; No role for fibrosis reportedNo phenotype for fibrosis reported ([@bib39])Epigen (EPGN)Fibrosis in nerves and neurological defects ([@bib12])No phenotype for fibrosis reported ([@bib13])

11. EGFR inhibitors as therapeutics {#sec11}
===================================

The use of tyrosine kinase inhibitors like Erlotinib and its family members, are able to reverse or inhibit fibrosis development in a variety of animal models. TGF-β induction, a hallmark of many fibrotic diseases, drives expression of EGFR ligands which themselves lead to EGFR activation. Modulators of TGF-β signaling, induction and activation are in development. Upstream of TGF-β signaling, there are several FDA approved drugs (Losartan, Pirfenidone and Tranilast) that have effects at lowering TGF-β levels in the host. Several other small molecules, antibodies and siRNAs target TGF-β itself and are currently in clinical trials for a variety of fibrotic and cancer related diseases ([@bib2]). EGFR activation induces the production of mucins (to assist in clearance of particles and debris) and IL-8 (a neutrophil recruiting chemokine) in addition to stimulating repair. Inhibitors of either overactive mucin production or antagonists of IL-8 could be useful in the modulation of a dysregulated EGFR response leading to resumption of control of host tissue repair. There are caveats for the use of tyrosine kinase inhibitors, specifically with respect to pulmonary toxicity. The use of Gefitinib has been reported to induce interstitial lung disease in patients treated for non-small cell lung cancer (NSCLC) ([@bib36], [@bib66]). TKIs are highly effective in treating EGFR positive cancers but their effect on normal tissue has not been well investigated.

12. Future directions {#sec12}
=====================

The development of severe lung disease leading to pulmonary fibrosis after SARS-CoV infection is a major complication of those who survived the SARS-CoV outbreak. Current research focuses on wound healing pathways that mediate tissue repair after injury, specifically the EGFR pathway. Specifically, we are studying how dysregulation of the EGFR pathway could lead to the development of pulmonary fibrosis in animal models of SARS-CoV. We hypothesize that targeted inhibition of EGFR, the proteins that activate EGFR or the proteins downstream of EGFR signaling could provide novel therapeutic interventions for pulmonary fibrosis patients. In addition, we believe that infections by other highly pathogenic respiratory viruses like MERS-CoV or future emerging respiratory viruses, could induce pulmonary fibrosis in patients. Understanding how the EGFR, wound healing and other pro-fibrotic pathways act after viral infection should lead to novel therapeutics in the future.
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